How physician obesity specialists use drugs to treat obesity

Obesity

Volumn 17, Issue 9, 2009, Pages 1730-1735

  Hendricks, Ed J ^a   Rothman, Richard B ^b   Greenway, Frank L ^c  

^a Center for Weight Management   (United States)

^b BeLite Medical Center   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIOBESITY AGENT; CARBIDOPA; PHENTERMINE; PRESCRIPTION DRUG;

ARTICLE; CLINICAL PRACTICE; DRUG COMBINATION; DRUG EFFECT; DRUG LABELING; DRUG UTILIZATION; EPIDEMIOLOGY; HUMAN; MEDICINE; OBESITY; PRACTICE GUIDELINE; QUESTIONNAIRE; RETROSPECTIVE STUDY; STATISTICS; TIME; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

5-HYDROXYTRYPTOPHAN; ANTI-OBESITY AGENTS; CARBIDOPA; DRUG COMBINATIONS; DRUG LABELING; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; OBESITY; PHENTERMINE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION DRUGS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SPECIALTIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WEIGHT LOSS;

EID: 69749110806     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.69     Document Type: Article

References (23)

1. Putnam JJ. Cases of myxoedema and acromegalia treated with benefit by sheep?s thyroids. Am J Med Sci 1893;106:125-148.
2. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999;20:805-875.
3. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151-184.
4. National Institutes of Health: NIH Consensus Development Conference Statement, Health Implications of Obesity. Ann Int Med 1985;103: 1973-1977.
5. National Institutes of Health, National Heart, Blood and Lung Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(Suppl 2): S51-S209.
6. Li Z, Maglione M, Tu W et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-546.
7. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
8. Rothman RB. Treatment of obesity with "combination" pharmacotherapy. Am J Ther, in press. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001;2: 199-211.
9. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001;2: 199-211.
10. Wadden TA, Berkowitz RI, Womble LG et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431-437.
11. Aydin N, Topsever P, Kaya A et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004;202:173-180.
12. Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004;30:159-167.
13. Kaya A, Aydin N, Topsever P et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004;58:582-587.
14. Haddock CK, Poston WS, Foreyt J P, DiBartolomeo JJ, Warner PO. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: a clinical program evaluation. Eat Weight Disord 2008;13: 95-101.
15. Frank A. The long-term management of obesity with continuing pharmacotherapy. Obes Res 2004;12:1821-1827.
16. Weintraub M, Sundaresan PR, Schuster B et al. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Clin Pharmacol Ther 1992;51:608-614.
17. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 2006;109:325-338.
18. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev 1998;3:271-280.
19. American Society of Bariatric Physicians. «http://www.asbp.org/ siterun-data/about-asbp/news.php?q = 770d63b79fe73fb00d7277f0b49285c0». Accessed 11 November 2008.
20. Tilley BC, Alarcon GS, Heyse SP et al. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med 1995;122:81-89.
21. Volanen I, Kallio K, Saarinen M et al. Arterial intima-media thickness in 13-year-old adolescents and previous antichlamydial antimicrobial use: a retrospective follow-up study. Pediatrics 2008;122:e675-e681.
22. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
23. Snow V, Barry P, Fihn SD et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;141:562-567.